Scott Kinlay

Scott Kinlay

Auto-generated profile, based on publicly available information

Scott Kinlay

VA Boston Healthcare System, Boston, USA

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2015 in Circulation Research
Verified
Journal Article
Closed access
PDF file
ATArun K. Thukkani
Arun K. Thukkani
SKScott Kinlay
Scott Kinlay
Advances in endovascular therapies during the past decade have broadened the options for treating peripheral vascular disease percutaneously. Endovascular treatment offers a lower risk alternative to open surgery in many patients with multiple comorbidities. Noninvasive physiological tests and arterial imaging precede an endovascular intervention and help localize the disease and plan the procedure. The timing and need for revascularization are broadly related to the 3 main clinical presentations of claudication, critical limb ischemia, and acute limb ischemia. Many patients with claudication can be treated by exercise and medical therapy. Endovascular procedures are considered when these fail to improve quality of life and function. In contrast, critical limb ischemia and acute limb ischemia threaten the limb and require more urgent revascularization. In general, endovascular treatments have greater long-term durability for aortoiliac disease than femoral popliteal disease. Infrapopliteal revascularization is generally reserved for critical and acute limb ischemia. Balloon angioplasty and stenting are the mainstays of endovascular therapy. New well-tested innovations include drug-eluting stents and drug-coated balloons. Adjunctive devices for crossing chronic total occlusions or debulking plaque with atherectomy are less rigorously studied and have niche roles. Patients receiving endovascular procedures need a structured surveillance plan for follow-up care. This includes intensive treatment of cardiovascular risk factors to prevent myocardial infarction and stroke, which are the main causes of death. Limb surveillance aims to identify restenosis and new disease beyond the intervened segments, both of which may jeopardize patency and lead to recurrent symptoms, functional impairment, or a threatened limb.

1 February 2016 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Closed access
PDF file
SKScott Kinlay
Scott Kinlay
Critical limb ischemia (CLI) is a clinical syndrome of ischemic pain at rest or tissue loss, such as nonhealing ulcers or gangrene, related to peripheral artery disease. CLI has a high short-term risk of limb loss and cardiovascular events. Noninvasive or invasive angiography help determine the feasibility and approach to arterial revascularization. An endovascular-first approach is often advocated based on a lower procedural risk; however, specific patterns of disease may be best treated by open surgical revascularization. Balloon angioplasty and stenting form the backbone of endovascular techniques, with drug-eluting stents and drug-coated balloons offering low rates of repeat revascularization. Combined antegrade and retrograde approaches can increase success in long total occlusions. Below the knee, angiosome-directed angioplasty may lead to greater wound healing, but failing this, any straight-line flow into the foot is pursued. Hybrid surgical techniques such as iliac stenting and common femoral endarterectomy are commonly used to reduce operative risk. Lower extremity bypass grafting is most successful with a good quality, long, single-segment autogenous vein of at least 3.5-mm diameter. Minor amputations are often required for tissue loss as a part of the treatment strategy. Major amputations (at or above the ankle) limit functional independence, and their prevention is a key goal of CLI therapy. Medical therapy after revascularization targets risk factors for atherosclerosis and assesses wound healing and new or recurrent flow-limiting disease. The ongoing National Institutes of Health–sponsored Best Endovascular Versus Best Surgical Therapy in Patients With Critical Limb Ischemia (BEST-CLI) study is a randomized trial of the contemporary endovascular versus open surgical techniques in patients with CLI.

26 March 2002 in Circulation
Verified
Journal Article
Closed access
SCSpeakers For The Vulnerable Plaque Conference
Speakers For The Vulnerable Plaque Conference
DBDonald Baim
Donald Baim
TBThomas J. Brady
Thomas J. Brady
SCS. Ward Casscells
S. Ward Casscells
MDMichael Dunne
Michael Dunne
BWBruce Wasserman
Bruce Wasserman

23 January 2013 in Journal of the American Heart Association
Verified
Journal Article
Open access
PZPayman Zamani
Payman Zamani
GSGregory G. Schwartz
Gregory G. Schwartz
AOAnders G. Olsson
Anders G. Olsson
NRNader Rifai
Nader Rifai
WBWeihang Bao
Weihang Bao
FIfor the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators
Background: In acute coronary syndromes, C ‐reactive protein ( CRP ) strongly relates to subsequent death, but surprisingly not to recurrent myocardial infarction. Other biomarkers may reflect different processes related to these outcomes. We assessed 8 inflammatory and vascular biomarkers and the risk of death and recurrent nonfatal cardiovascular events in the 16 weeks after an acute coronary syndrome. Methods and Results: We measured blood concentrations of CRP , serum amyloid A ( SAA ), interleukin‐6 ( IL ‐6), soluble intercellular adhesion molecule ( ICAM ), soluble vascular cell adhesion molecule ( VCAM ), E ‐selectin, P ‐selectin, and tissue plasminogen activator antigen ( tPA ) 24 to 96 hours after presentation with acute coronary syndrome in 2925 subjects participating in a multicenter study. Biomarkers were related to the risk of death, and recurrent nonfatal acute coronary syndromes (myocardial infarction or unstable angina) over 16 weeks using C ox proportional hazard models. On univariate analyses, baseline CRP ( P =0.006), SAA ( P =0.012), and IL‐6 ( P <0.001) were related to death, but not to recurrent nonfatal acute coronary syndromes. VCAM and tPA related to the risk of death ( P <0.001, P =0.021, respectively) and to nonfatal acute coronary syndromes ( P =0.021, P =0.049, respectively). Adjusting for significant covariates reduced the strength of the associations; however, CRP and SAA continued to relate to death. Conclusions: In acute coronary syndromes, the CRP inflammatory axis relates to the risk of death and may reflect myocardial injury. VCAM and tPA may have greater specificity for processes reflecting inflammation and thrombosis in the epicardial arteries, which determine recurrent coronary events.

6 October 2009 in Vascular Medicine
Verified
Journal Article
Open access
PZPayman Zamani
Payman Zamani
JKJames Kaufman
James Kaufman
SKScott Kinlay
Scott Kinlay
Arteriovenous fistulae in the arm are commonly used for hemodialysis in end-stage renal disease. Although physiological steal with reverse flow in the artery distal to the fistula is common, hand ischemia or infarction are rare. The ischemic steal syndrome (hand or forearm ischemia) is usually a result of arterial disease proximal or distal to the fistula and/or poor collateral supply to the hand. The diagnosis is primarily clinical; however, markedly reduced digital pressures and pulse volume recordings support the diagnosis. Management requires imaging for focal stenoses or disease in arteries proximal and distal to the fistula from the aorta to the hand. We present a case caused by subclavian artery occlusion that was initially missed due to focusing investigation only on the fistula. We describe the percutaneous treatments and surgical revisions that attempt to restore flow to the hand without compromising the fistula.

8 November 2011 in Circulation
Verified
Journal Article
Closed access
PDF file
SKScott Kinlay
Scott Kinlay